Covenant Asset Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.24M Buy
8,964
+132
+1% +$134K 1.24% 24
2025
Q4
$9.49M Sell
8,832
-24
-0.3% -$22.9K 1.12% 20
2025
Q3
$6.76M Buy
8,856
+103
+1% +$76.6K 0.76% 28
2025
Q2
$6.82M Buy
8,753
+122
+1% +$94.8K 1.01% 23
2025
Q1
$7.13M Sell
8,631
-2,917
-25% -$2.43M 1.57% 15
2024
Q4
$8.91M Sell
11,548
-432
-4% -$358K 1.37% 16
2024
Q3
$10.6M Buy
11,980
+74
+0.6% +$66.5K 1.67% 12
2024
Q2
$10.8M Sell
11,906
-84
-0.7% -$67.2K 1.71% 11
2024
Q1
$9.33M Buy
11,990
+48
+0.4% +$34.2K 1.53% 14
2023
Q4
$6.96M Buy
11,942
+457
+4% +$267K 1.25% 15
2023
Q3
$6.17M Buy
11,485
+25
+0.2% +$12.9K 1.63% 10
2023
Q2
$5.37M Sell
11,460
-38
-0.3% -$15.9K 1.36% 17
2023
Q1
$3.95M Buy
11,498
+1,144
+11% +$386K 0.94% 34
2022
Q4
$3.79M Buy
10,354
+235
+2% +$83.3K 0.9% 38
2022
Q3
$3.27M Buy
10,119
+1,637
+19% +$519K 0.93% 30
2022
Q2
$2.75M Buy
+8,482
New +$2.55M 0.87% 41

Other funds holding LLY

Covenant Asset Management's LLY Position: Q1 2026 in Review

Covenant Asset Management increased its Eli Lilly (LLY) stake by 1.5% in Q1 2026, buying an estimated $134K and bringing the position to 8,964 shares worth $8.24M. The position accounts for 1.24% of the portfolio, ranked #24.

Covenant Asset Management first reported a position in LLY in Q2 2022 and has held it in 16 quarters since. The position peaked at $10.8M in Q2 2024. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Covenant Asset Management held 8,964 shares of Eli Lilly worth $8.24M as of Q1 2026.
  • Covenant Asset Management bought 132 Eli Lilly shares in Q1 2026, an estimated $134K.
  • Eli Lilly made up 1.24% of Covenant Asset Management's portfolio in Q1 2026, its #24 holding.
  • Covenant Asset Management first reported a position in Eli Lilly in Q2 2022 and has held it in 16 quarters since.
  • Covenant Asset Management's Eli Lilly position peaked at $10.8M in Q2 2024.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Covenant Asset Management's 13F filing for Q1 2026, filed 14 Apr 2026.